Merck & Co., Inc. and Lundbeck discontinue joint development program for gaboxadol, an investigational compound for insomnia
Merck & Co., Inc. and H. Lundbeck A/S announced today the discontinuation ofthe joint development program for gaboxadol, an investigational new medicinefor the treatment of insomnia currently in phase III development. Data fromrecently completed clinical studies suggest that the overall clinical profilefor gaboxadol in insomnia does not support further development.